Mary Chapman, features writer —

Mary graduated from Wayne State University with a degree in journalism. She began her career at United Press International, then spent a decade reporting for the Bureau of National Affairs, Inc. (now Bloomberg Industry Group). Mary has written extensively for The New York Times, and her work has appeared in publications such as Time, Newsweek, Fortune, and the Chicago Tribune. She’s won a Society of Professional Journalists award for outstanding reporting.

Articles by Mary Chapman

Cold Agglutinin Disease and Advocacy

If you or a family member has cold agglutinin disease (CAD), you may be interested in getting involved with health advocacy efforts, which promote health and access to care. What is CAD? CAD is a rare autoimmune disorder in which exposure to cold temperatures, those between 32 to 50…

NORD’s 6th ‘State Report Card’ Notes Progress, Raises Concerns

While progress was made last year on newborn screening and other policy issues critical to rare disease patients, a “State Report Card” argues that many concerns — notably out-of-pocket costs for prescription medicines and access to affordable comprehensive care — still need attention. Those were the findings of the…

Emotional Responses to CAD Diagnosis

After receiving a diagnosis of cold agglutinin disease (CAD), you may experience emotions that range from relief to shock. You also may go through the stages of grief, which is completely normal. The following overview may help you understand what to expect, and how to cope with any emotional responses…

NORD’s Caregiver Respite Program Continues Through Pandemic

Caring for a loved one with a rare disease, especially during these uncertain times, demands significant time, attention, patience, and dedication. To help meet that need, the National Organization for Rare Disorders (NORD)’s Rare Caregiver Respite Program may be a helpful resource. The program seeks to give a…

The CADENCE Registry

To advance understanding of cold agglutinin disease (CAD) and better support patients globally, Sanofi Genzyme has launched a global registry. The CADENCE (Cold Agglutinin Disease Real World Evidence) Registry is the first major prospective data repository for CAD patients. Following is information about the registry and its potential benefits. About CAD…

Summary of CAD Medications

Avoiding cold conditions, dressing appropriately for the cold, or living in warm climates is often sufficient to manage mild cases of cold agglutinin disease (CAD). However, if you have a more severe case of the disease, you may require medical treatment. Here’s a summary of those medications. About CAD CAD…